Other languages LianBio

Equities

LIANY

US53000N1081

Delayed OTC Markets Other stock markets 13:55:42 2024-05-06 EDT			5-day change	1st Jan Change
0.3148 ^USD	+3.23%		-3.05%	-92.96%

03-18	LianBio(OTCPK:LIAN.Y) dropped from NASDAQ Composite Index	CI
03-15	ADRs End Lower; Akso Health Group Declines 23%	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LianBio to Start Winding Down Operations; Complete Dissolution Expected in 2027	02-13
LianBio Announces Completion of Strategic Review	02-13
Nanobiotix : transfert de droits sur NBTXR3 en Asie	12-27
Nanobiotix Partner Transfers Asian Commercialization Rights for Oncology Therapy to Johnson & Johnson Unit	12-27
Sector Update: Health Care Stocks Mixed Premarket Tuesday	12-26
LianBio Assigns Rights to Nanobiotix's Oncology Therapy in China, Other Asian Markets to Janssen Pharmaceutica	12-26
LianBio Enters into Agreement with Janssen Pharmaceutica to Assign its Rights for NBTXR3 in China and Other Asian Markets	12-26
LianBio Finance Chief Resigns, Names Interim CFO	12-20
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading	12-20
LianBio CEO Yizhe Wang Resigns; Board Member Adam Stone Named in Interim	12-19
Lianbio Announces Resignation of Yizhe Wang as Member of the Board of Directors	12-19
Lianbio Announces Chief Executive Officer Changes	12-19
LianBio to Communicate an Update on the Ongoing Strategic Review in the First Quarter of 2024	12-18
LianBio Rejects Concentra Biosciences' Unsolicited Acquisition Proposal	12-07
Concentra Biosciences, LLC cancelled the acquisition of LianBio from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others.	12-05
LianBio Receives Unsolicited Proposal From Concentra Biosciences to be Acquired for $4.30 Per Share Plus Contingent Value Right	12-01
LianBio Q3 Loss Widens	11-13
LianBio Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13
LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis	23-10-30
LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023	23-10-25

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages LianBio

Equities

LIANY

US53000N1081

Other languages

Filters